An inflammatory eruption associated with recombinant human IL-6.
Interleukin 6 (IL-6) is an endogenous cytokine with multiple biological functions, including amplification of the inflammatory response. Recombinant human IL-6, administered as part of a chemotherapeutic regimen, has recently been shown to cause regression of certain types of malignant tumours. We report a patient who developed a cutaneous eruption consisting of coalescent, erythematous, scaling macules and papules after administration of recombinant human IL-6, given as part of her chemotherapy for ductal carcinoma of the breast.
Fleming
T E
TE
Department of Dermatology, University Hospitals of Cleveland, Ohio 44106.
Mirando
W S
WS
Soohoo
L F
LF
Cooper
B W
BW
Zaim
M T
MT
Lazarus
H M
HM
Elmets
C A
CA
D000328:Adult; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000009:adverse effects*; D011994:Recombinant Proteins / Q000009:adverse effects; D012867:Skin / Q000473:pathology
D015850:Interleukin-6; D011994:Recombinant Proteins